ANG Lifesciences India Ltd
₹ 20.3
9.99%
01 Apr
12:55 p.m.
About
Incorporated in 2006, ANG Lifesciences
India Ltd is in the business of pharmaceuticals products & formulations, and packaging and printing.[1]
Key Points
- Market Cap ₹ 26.5 Cr.
- Current Price ₹ 20.3
- High / Low ₹ 39.7 / 17.6
- Stock P/E
- Book Value ₹ 50.0
- Dividend Yield 0.00 %
- ROCE -3.54 %
- ROE -13.8 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.40 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -6.58% over past five years.
- Company has a low return on equity of -7.31% over last 3 years.
- Promoters have pledged 44.9% of their holding.
- Earnings include an other income of Rs.1.29 Cr.
- Company has high debtors of 264 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34.50 | 36.84 | 54.92 | 66.93 | 75.13 | 121.27 | 126.08 | 154.24 | 348.52 | 206.82 | 131.30 | 89.73 | 86.47 | |
| 29.61 | 33.72 | 50.19 | 60.43 | 67.83 | 109.63 | 113.65 | 138.91 | 282.98 | 195.15 | 121.75 | 90.75 | 84.82 | |
| Operating Profit | 4.89 | 3.12 | 4.73 | 6.50 | 7.30 | 11.64 | 12.43 | 15.33 | 65.54 | 11.67 | 9.55 | -1.02 | 1.65 |
| OPM % | 14.17% | 8.47% | 8.61% | 9.71% | 9.72% | 9.60% | 9.86% | 9.94% | 18.81% | 5.64% | 7.27% | -1.14% | 1.91% |
| 0.12 | 0.09 | 0.21 | 0.25 | 0.69 | 0.23 | 0.42 | 0.75 | 0.95 | 9.84 | -0.89 | 1.99 | 1.29 | |
| Interest | 1.51 | 1.66 | 1.66 | 1.77 | 1.85 | 2.64 | 3.22 | 3.98 | 8.31 | 10.92 | 9.77 | 7.64 | 6.86 |
| Depreciation | 3.05 | 0.95 | 1.06 | 1.17 | 1.19 | 1.12 | 1.23 | 2.24 | 5.12 | 8.52 | 7.75 | 6.27 | 5.65 |
| Profit before tax | 0.45 | 0.60 | 2.22 | 3.81 | 4.95 | 8.11 | 8.40 | 9.86 | 53.06 | 2.07 | -8.86 | -12.94 | -9.57 |
| Tax % | 55.56% | 31.67% | 25.23% | 25.98% | 24.65% | 30.33% | 27.50% | 26.47% | 25.18% | 131.88% | -2.48% | -20.02% | |
| 0.19 | 0.40 | 1.65 | 2.82 | 3.72 | 5.65 | 6.10 | 7.25 | 39.71 | -0.66 | -8.65 | -10.34 | -7.77 | |
| EPS in Rs | 0.21 | 0.43 | 1.79 | 3.07 | 2.86 | 4.35 | 4.69 | 5.58 | 30.55 | -0.51 | -6.62 | -7.92 | -5.95 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | 2.61% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -7% |
| 3 Years: | -36% |
| TTM: | -19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 27% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -12% |
| 3 Years: | -38% |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 9% |
| 3 Years: | -7% |
| Last Year: | -14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.68 | 3.68 | 3.68 | 3.68 | 5.18 | 5.18 | 5.18 | 5.18 | 10.37 | 13.06 | 13.06 | 13.06 | 13.06 |
| Reserves | -0.97 | -0.57 | 1.09 | 3.81 | 17.99 | 23.58 | 29.37 | 36.17 | 73.11 | 72.48 | 64.01 | 53.75 | 52.20 |
| 11.03 | 10.15 | 11.77 | 14.01 | 17.42 | 21.90 | 20.83 | 42.40 | 60.99 | 55.56 | 59.36 | 70.58 | 78.12 | |
| 11.44 | 12.59 | 18.95 | 25.34 | 27.57 | 30.24 | 38.69 | 58.49 | 124.21 | 111.40 | 81.00 | 71.28 | 80.68 | |
| Total Liabilities | 25.18 | 25.85 | 35.49 | 46.84 | 68.16 | 80.90 | 94.07 | 142.24 | 268.68 | 252.50 | 217.43 | 208.67 | 224.06 |
| 9.04 | 8.78 | 9.02 | 8.90 | 9.47 | 20.60 | 20.94 | 21.89 | 82.32 | 78.68 | 53.35 | 52.63 | 49.79 | |
| CWIP | -0.00 | -0.00 | -0.00 | 0.07 | 11.57 | 0.16 | 0.23 | 0.40 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 3.52 | 3.52 | 3.52 | 3.52 | 3.52 |
| 16.12 | 17.05 | 26.45 | 37.85 | 47.10 | 60.12 | 72.88 | 119.93 | 182.84 | 170.30 | 160.56 | 152.52 | 170.75 | |
| Total Assets | 25.18 | 25.85 | 35.49 | 46.84 | 68.16 | 80.90 | 94.07 | 142.24 | 268.68 | 252.50 | 217.43 | 208.67 | 224.06 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.58 | 3.13 | 1.86 | 2.73 | 0.88 | 7.46 | 4.83 | -11.18 | 27.39 | 26.01 | -13.13 | -2.29 | |
| -2.14 | -2.32 | -2.92 | -2.56 | -13.40 | -0.77 | -1.66 | -7.79 | -42.50 | -9.35 | 20.02 | -1.63 | |
| -1.43 | -0.89 | 1.63 | -0.29 | 13.10 | -3.80 | -3.95 | 18.81 | 15.29 | -16.75 | -7.00 | 3.92 | |
| Net Cash Flow | 0.02 | -0.08 | 0.56 | -0.12 | 0.57 | 2.89 | -0.77 | -0.16 | 0.17 | -0.08 | -0.12 | -0.01 |
| Free Cash Flow | 2.91 | 2.43 | 0.55 | 1.61 | -12.38 | 6.62 | 3.19 | -15.25 | -11.96 | 15.58 | 5.93 | -6.41 |
| CFO/OP | 75% | 103% | 48% | 54% | 26% | 84% | 60% | -69% | 43% | 252% | 3% | -186% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 79.67 | 62.22 | 108.86 | 139.39 | 156.19 | 125.66 | 133.34 | 139.10 | 103.67 | 137.85 | 192.56 | 264.24 |
| Inventory Days | 83.99 | 84.14 | 46.81 | 44.62 | 53.41 | 27.18 | 41.03 | 67.62 | 46.29 | 92.90 | 143.34 | 227.95 |
| Days Payable | 129.49 | 129.88 | 133.28 | 163.44 | 153.96 | 90.63 | 105.80 | 158.84 | 105.16 | 153.93 | 243.56 | 333.86 |
| Cash Conversion Cycle | 34.17 | 16.48 | 22.39 | 20.58 | 55.64 | 62.21 | 68.56 | 47.88 | 44.80 | 76.83 | 92.34 | 158.34 |
| Working Capital Days | 28.25 | 18.73 | 10.23 | 14.40 | 48.29 | 39.70 | 52.60 | 47.14 | 22.05 | 30.88 | 74.97 | 71.80 |
| ROCE % | 13.65% | 16.74% | 26.04% | 29.34% | 21.90% | 23.56% | 21.92% | 19.90% | 53.78% | 8.51% | 1.78% | -3.54% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capacity Utilization - Sterile Dry Powder Injection % |
|
||||||||||
| Total Employee Strength Number |
|||||||||||
| Installed Capacity - Tablets (Unit 4 & 5) Million Pieces per Annum |
|||||||||||
| Trade Receivables Turnover Ratio Times |
|||||||||||
| Capacity Utilization - Tablets (Unit 4 & 5) % |
|||||||||||
| Utilized Capacity - Sterile Dry Powder Injection Million Pieces per Annum |
|||||||||||
| Utilized Capacity - Tablets (Unit 4 & 5) Million Pieces per Annum |
|||||||||||
| Installed Capacity - Soft Gelatin Capsules (Unit 6) Million Pieces per Annum |
|||||||||||
| Installed Capacity - Sterile Dry Powder Injection Vials Million Pieces per Annum |
|||||||||||
| Total Product Portfolio base Number |
|||||||||||
| Utilized Capacity - Sterile Dry Powder Injection Lakh Pcs |
|||||||||||
| Capacity Utilization - Soft Gelatin Capsules (Unit 6) % |
|||||||||||
| Utilized Capacity - Soft Gelatin Capsules (Unit 6) Million Pieces per Annum |
|||||||||||
| Installed Capacity - Sterile Dry Powder Injection Vials Lakh Pcs |
|||||||||||
Requires Premium
Requires Premium
Documents
Announcements
- Closure of Trading Window 25 Mar
-
Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 31-12-2025
14 Feb - Board approved Q3 & 9M FY26 unaudited results (14-Feb-2026); standalone Q3 loss ₹497.70 lakh., consolidated loss reported too, auditor review unmodified.)","checklist":["Read and extract key facts …
-
Board Meeting Outcome for Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 31-12-2025
14 Feb - Approved unaudited Q3 and nine-month FY26 results; standalone Q3 loss ₹497.70 lakh; limited review unmodified.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
6 Feb - Revised secretarial compliance report for FY2024-25; delayed share capital audit reconciliation for June and Sept 2024.
-
Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended And Nine Months Ended On 31St December, 2025.
5 Feb - Board meeting 14-Feb-2026 to approve Q3/9M FY2026 unaudited results (ended 31-Dec-2025); trading window closed.
Business Overview:[1][2][3]
ANGLIL is a part of the ANG Group which is a WHO-GMP–certified consortium of pharmaceutical companies. The company is engaged in the manufacturing of pharmaceuticals & allied products which include finished formulations in Non-Beta Lactam, Beta Lactam, Cephalosporin, and Carbapenem segments.